论文部分内容阅读
目的评估瑞芬太尼静脉镇痛的安全性与有效性。方法 40例初产妇随机均分为PCIA组与CSEA组,PCIA组:瑞芬太尼镇痛泵,背景剂量0.05μg/(kg·min),追加剂量0.2μg/kg,锁定时间2min。CSEA组:蛛网膜下腔注入罗哌卡因2mg+舒芬太尼5μg,硬膜外镇痛泵:舒芬太尼45μg+罗哌卡因80mg,背景剂量3ml/h,追加剂量7ml,锁定时间15min。监测并记录两组产妇Bp、HR、SpO_2,VAS评分,不良反应,胎儿Apart评分。结果两组产妇镇痛后各时点VAS评分均明显下降,镇痛后各时点CSEA组较PCIA组VAS评分下降更为明显(P<0.05),两组头晕发生率有明显差异(P<0.01)。结论与罗哌卡因复合舒芬太尼CSEA组比较,瑞芬太尼PCIA组VAS评分高,对不愿、不需、不能行椎管内镇痛的产妇是一种安全有效的选择。
Objective To evaluate the safety and efficacy of remifentanil intravenous analgesia. Methods 40 cases of primipara were randomly divided into PCIA group and CSEA group, PCIA group: remifentanil analgesia pump, the background dose of 0.05μg / (kg · min), the additional dose of 0.2μg / kg, locking time 2min. CSEA group: subarachnoid injection of ropivacaine 2mg + sufentanil 5μg, epidural analgesia pump: sufentanil 45μg + ropivacaine 80mg, the background dose of 3ml / h, the additional dose of 7ml, locking time 15min . Two groups of maternal Bp, HR, SpO_2, VAS scores, adverse reactions, fetal Apart score were monitored and recorded. Results The VAS scores of the two groups were significantly decreased at different time points after pain relief. The VAS score of CSEA group was significantly lower than that of PCIA group at each time point (P <0.05), and the incidence of dizziness was significantly different between the two groups (P < 0.01). Conclusion Compared with the ropivacaine compound sufentanil CSEA group, the remifentanil PCIA group has a high VAS score, which is a safe and effective choice for women who are reluctant, not required, and can not receive intraspinal analgesia.